(No ratings)
Dr. Patrick Joseph Leavey, MD is a medical oncologist in Dallas, TX specializing in medical oncology, pediatric hematology, general pediatrics and general practice. He graduated from Royal College of Physicians and Surgeons-Ireland in 1986 and has 40 years of experience. Dr. Patrick Joseph Leavey, MD is affiliated with UT Southwestern Medical Center, Children’s Medical Center Dallas and Children's Medical Center Dallas.
Dr. Patrick Joseph Leavey, MD graduated from Royal College of Physicians and Surgeons-Ireland in 1986. He completed residency at St. Vincents Hospital - Dublin Ireland. He has a state license in Texas.
Medical School: Royal College of Physicians and Surgeons-Ireland (1986)
Residency: St. Vincents Hospital - Dublin Ireland (1989)
Licensed In: Texas
Dr. Patrick Joseph Leavey, MD is associated with these hospitals and organizations:
Dr. Patrick Joseph Leavey, MD does not have any reviews yet, be the first to leave a review of Dr. Patrick Joseph Leavey, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Patrick Joseph Leavey, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Novartis Pharmaceuticals Corporation |
$78
LEE011 $78 |
|---|---|
| Spark Therapeutics, Inc. |
$19
$19 |
| Food and Beverage | $98 |
|---|
Dr. Patrick Joseph Leavey, MD has received 70 research payments totaling $712,414.
Dr. Patrick Leavey is a specialist in general practice, medical oncology, and pediatric hematology/oncology. He graduated from Royal College of Surgeons in Ireland and then he performed his residency at The Children's Hospital, Denver. His clinical interests encompass sarcoma (bone and soft tissue cancer). Awards and/or distinctions Dr. Leavey has received include Texas Super Doctors; D Magazine Best Doctor; and D Magazine Best Pediatric Specialist. He is conversant in Spanish. Dr. Leavey is professionally affiliated with UT Southwestern Medical Center. His practice in Dallas, TX is open to new patients as reported by Yext.